- Erythematosquamous palmoplantar lesions2007 | Faculty of Physical Education and Sport
- Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab2021 | Third Faculty of Medicine
- Erythematosquamous palmoplantar lesions2007 | First Faculty of Medicine
- Adalimumab biosimilar-induced severe paradoxical palmoplantar pustulosis in a patient with psoriasis and psoriatic arthritis successfully treated with ixekizumab2022 | Third Faculty of Medicine
- Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP2001 | Faculty of Medicine in Hradec Králové
- Acitretin Therapy of Palmoplantar Pustulosis Combined with UV-A and 8-MOP Topically1999 | Faculty of Medicine in Hradec Králové
- Formation of keto-type ceramides in palmoplantar keratoderma based on biallelic KDSR mutations in patients2022 | Faculty of Pharmacy in Hradec Králové
- Komentář k práci V. Černý, E. Crubezy: A possible case of palmoplantar pustulosis and seronegative spondylarthropathies in skeletal samples1995 | Second Faculty of Medicine
- SAPHO - the rare diagnosis2017 | Faculty of Medicine in Pilsen
- Apremilastum - new drug for psoriasis management2017 | Faculty of Medicine in Hradec Králové
- EMQN Best Practice guidelines for diagnostic testing of mutations causing non-syndromic hearing impairment at the DFNB1 locus2013 | Second Faculty of Medicine
- Management of psoriasis in adults and children by IL-17 A inhibitor secukinumab biologic therapy2020 | Publication without faculty affiliation
- First case of pachyonychia congenita in the Czech Republic2015 | Second Faculty of Medicine
- Pityriasis rubra pilaris.2011 | First Faculty of Medicine
- Pustular psoriasis and related pustular skin diseases2018 | Faculty of Medicine in Pilsen
- A European prospective, randomized placebo-controlled doubleblind Study on the efficacy and safety of Dr Michaels(R) (also branded as Soratinex(R)) product family for stable chronic plaque psoriasis2016 | Second Faculty of Medicine
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial2018 | First Faculty of Medicine